Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: amc who wrote (9043)	6/3/1998 6:18:00 PM
From: Philippe J. Dor	Read Replies (2) \| Respond to of 23519

Shares Of Some Impotence-Drug Makers Slide On Comparison With Viagra June 03, 1998 2:20 PM NEW YORK -(Dow Jones)- Shares of several makers of impotence drugs were under pressure Wednesday after a story in The Wall Street Journal reported that patients' first choice will likely be Pfizer Inc.'s blockbuster Viagra, despite the success of other drugs. The article mentioned Zonagen Inc., MacroChem Corp. and Vivus Inc., which all have clinical trial results on their products being presented this week at the American Urological Association meeting in San Diego. Researchers said that none of the other drugs has been directly compared with Viagra. However, they all have more side effects or are more difficult to use than Viagra, the article said. "The stocks are definitely reacting to the Journal article and not the clinical results," said Edmund Debler, an analyst at Mehta Partners. At the Urological Association meeting Tuesday, researchers presented data that indicated Zonagen's oral drug Vasomax was well tolerated in Phase III, or late-stage, trials. Researchers also said Tuesday that data from a new study confirms the safety and efficacy of MacroChem's Topiglan gel for treatment of erectile dysfunction. Data was presented Tuesday that indicated Vivus's Muse treatment, which is inserted directly into the urethra, was less effective than had been believed. In afternoon trading, shares of Vivus (VVUS) were down $1.563, or 18%, at $7.188. MacroChem (MCHM) shares slipped 43.8 cents, or 3.9%, to $10.938, and shares of Zonagen (ZONA) declined $4.688, or 13%, to $32.063. TAP Holdings Inc. was also mentioned in the article. The company, a joint venture of Abbott Laboratories and Takeda Chemical Industries Ltd. of Japan, is developing apomorphine, which acts directly on the brain to create erections. However, shares of Abbott Labs (ABT) were up 12.5 cents at $36.688. -By Jennifer Fron Mauer; 201-938-5287; jennifer-fron.mauer@cor.dowjones.com Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.

To: amc who wrote (9043)	6/3/1998 6:33:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

To anyone, As a shareholder what would it take to get this company to agree to a buy out by a large pharmaceutical company that would know how to effectively promote MUSE and doesn't roll over and play dead when times such as today occur? We now have a share price of $7 1/16 which is well below where we were when Vivus had no product approved, had no international sales agreements and had no factory to produce MUSE. The management obviously doesn't give a damn about "shareholder value" or else they would act accordingly. It's too bad that a fairly decent product is owned by a company with no management skills. We need a buyout ASAP. After today, compare our market cap to that of the other NASDAQ ED players who only have pie in the sky to sell and substantial earning loses. Someone once told me that on average it costs a company at least $300 million dollars to get a drug out on the market. After todays close we now have a company that once book value is subtracted has a market cap of about 115 million. In other words only about 1/3 of what it costs to research, market and develop the product. This is sickening to say the least! I would rather hear of the companies sale than anything else including plant approval and much higher script numbers. Get a decent player to take the helm and MUSE will command a value at least twice of the present market cap.

To: amc who wrote (9043)	6/3/1998 7:07:00 PM
From: Tunica Albuginea	Read Replies (2) \| Respond to of 23519

amc thank you for your comment: <<After looking at the price history of vvus i can certainly understand your hostility toward Pfizer but i also believe there is a sucker born every minute. Please keep buying vvus to prove my later point! >>. From reviewing your profile's only other post Message 2586810 <<<< To: +James O'Brien (11 ) From: +amc Reply #12 Wednesday, Oct 29 1997 5:21PM ET Are you the same people who demanded lower commissions because you didn't need a full service company to hold your hands? >>> I will assume you are a broker. Statistically only one in twenty brokers knows his job, chuckle chuckle. I have difficulty placing you, with only one sample for analysis, in the correct camp.; however judging by the lack of any ( medical ) data or any other data in your post, which is thus reduced to pure opinion, I think we can safely assume that you are an average guy, ie belonging to the majority of 19. While you are giving us your unadulterated opinion, I would also appreciate knowing from you, at what point in time should I get really hostile with Pfizer: i.e., how many cardiovascular deaths and how many blind people do you think is a reasonable price/earnings ratio for this stock, TA PS As a friendly gesture, I will help you keep tab. So far we've had 5 documented deaths. Here are 2 more Message 4710596 No blind people ( yet ). By the way are you one of those brokers described in the above URL ? "Investors and analysts have not been overly concerned about deaths on Viagra and expect that the media will make a bigger deal about them than is warranted ". One mor question: are any of your Urologists advisers part of this other group, in the same URL " Certainly, here at the American Urological Association meeting, Viagra fervor has been undiminished amid the occasional reports of deaths and ocular side effects ". Don't get hot now, I am just asking .